Online Mendelian Inheritance in Man (OMIM)

人类在线孟德尔遗传(OMIM®)是人类的一项基础性资源，目前已进入第55个年头 遗传学和基因组学。OMIM的目标是通过以下方式扩大对人类生物学和疾病的理解 提供有关日益复杂的信息的及时、权威、易于访问和可计算的知识库 以及人类基因与遗传疾病和特征之间的微妙关系。OMIM提供多样化的服务 科学界，包括临床遗传学家、卫生保健提供者、基础、模式生物、翻译 以及临床研究人员和生物信息学家以及这些领域的教育工作者和学生。OMIM.org是 全球每天有超过25,000名独立用户访问。OMIM的核心任务是命名和分类 孟德尔表型(性状和疾病)以及表型与引起疾病的基因的关系 他们。这是通过专家评审、评估和同行评审的生物医学摘要来完成的 由具有数十年经验的生物医学家和医学博士和博士科学作家组成的专家团队撰写的文献 合成大量信息并将其纳入丰富的结构化基因和表型条目中， 全面的临床概要，以及一个基因图谱/病态图谱，从中创建了表型系列。AS 截至2020年12月31日，OMIM包括超过25,692个条目，7,754个临床概要和489个表型 系列片。MIM号码是国际公认的孟德尔疾病的唯一识别符，并出现 贯穿了整个生物医学文献。OMIM词条和临床概要被映射到受控词汇表 ICD10、SNOMED、HPO和UMLS等资源。这些映射是可搜索和可用的 通过该API方便了计算调查和数据挖掘，以及 OMIM数据，以增强分析管道、传播和可计算性。此外，OMIM还利用数据 从各种其他资源中增加其独特的内容，并与其他信息学合作 资源和管理工作，如ClinVar、Clingen和Monch Initiative，以协调数据内容。 拓展和改进OMIM，使其成为临床、学术和商业领域的卓越资源 研究社区，我们通过增加专家科学和生物信息学扩大了我们目前的覆盖范围 并将继续加强与其他实体的结构兼容性，保持行业最佳做法 在数据库和软件开发方面，并以有针对性的成本提供Web服务和REST API- 有效的方法。我们将增强高效和自动化的过程，以挖掘 管理流程，并引入新的数据可视化和搜索功能。为了进一步优化最终用户 经验丰富，我们有经验丰富的用户支持人员提供技术援助和培训。我们经常 征求反馈和社区意见，以改进我们资源的功能特性和免费访问。 OMIM是临床医学、模式生物研究以及疾病基因和疾病研究的重要资源 治疗方面的发现。

Online Mendelian Inheritance in Man (OMIM®), currently in its 55th year, is a foundational resource in human genetics and genomics. OMIM's goal is to expand the understanding of human biology and disease by providing a timely, authoritative, easily accessible, and computable knowledgebase of the increasingly complex and nuanced relationships between human genes and genetic disorders and traits. OMIM serves diverse scientific communities, including clinical geneticists, health care providers, basic, model organism, translational and clinical researchers and bioinformaticians as well as educators and students in these fields. OMIM.org is accessed by over 25,000 unique daily users worldwide. OMIM's core mission is the naming and classification of Mendelian phenotypes (traits and diseases) and the relationship of the phenotypes to the genes that cause them. This is accomplished by expert review, evaluation, and summary of the peer-reviewed biomedical literature by an expert staff of biocurators and MD and PhD science writers who have decades of experience in synthesizing and incorporating substantive information into rich, structured gene and phenotype entries, comprehensive clinical synopses, and a GeneMap/Morbid Map from which Phenotypic Series are created. As of 31 December 2020, OMIM includes over 25,692 entries, 7,754 clinical synopses, and 489 Phenotypic Series. MIM numbers are internationally recognized as unique identifiers of Mendelian disorders and appear throughout the biomedical literature. OMIM entries and clinical synopses are mapped to controlled-vocabulary resources such as ICD10, SNOMED, HPO, and the UMLS. These mappings are searchable and available through the API to facilitate computational survey and data mining, as well as the functional integration of OMIM data to enhance analysis pipelines, dissemination, and computability. In addition, OMIM leverages data from a variety of other resources to augment its unique content and collaborates with other informatics resources and curation efforts such as ClinVar, ClinGen, and the Monarch Initiative to harmonize data content. To broaden and improve OMIM as the preeminent resource for the clinical, academic, and commercial research community, we have expanded our current coverage by adding expert scientific and bioinformatics staff and will continue to enhance its structural compatibility with other entities, maintain industry best practices in database and software development, and provide Web Services and REST API in a targeted and cost- effective way. We will augment efficient and automated processes to mine the biomedical literature in the curation process and introduce new data visualizations and search functions. To further optimize the end-user experience, we have experienced user support staff to provide technical assistance and training. We regularly solicit feedback and community input to improve the functional features and free accessibility of our resource. OMIM is an essential resource for clinical medicine, model organism research, and disease gene and therapeutic discovery.